Top

Published in:

01-11-2021 | Arthritis | Systematic Review

“Platelet-rich plasma holds promise in management of rheumatoid arthritis”—systematic review

Authors: Girinivasan Chellamuthu, Sathish Muthu, Manish Khanna, Venus Khanna

Published in: Rheumatology International | Issue 11/2021

Abstract

The treatment of rheumatoid arthritis (RA) has been closely evolving with an understanding of disease pathogenesis with disease modifying anti-rheumatoid drugs (DMARDS) and Biologic DMARDS being the main stay. platelet rich plasma (PRP) has been the center of research in many specialties in the past decade. Its ability to stop and reverse inflammation have attracted researchers to try PRP in RA. A systematic review of studies on PRP in RA is lacking. The study protocol was prospectively registered in PROSPERO. Detailed search of Cochrane, Scopus, Medline, Embase, and Web of science databases were made to identify the relevant articles till Sep 2020 following Cochrane and PRISMA guidelines. Number of subjects, Animal model used, cell lines used for the study, method of induction of arthritis, PRP dose, concentration used, frequency of administration and clinical, histologic, and molecular changes from baseline following PRP use were extracted and analysed. Eight studies were included for the review. Four of these were in-vitro studies. Two were exclusive animal studies. One study analysed the effects of PRP in RA in both animal models (mice) and Hela cell lines. One study was a report of a series of patients of resistant RA treated with PRP. In the in vitro studies while platelets increase the migration and invasion of RA-FLS, they suppressed the inflammation on the whole. Available animal studies and the Human study have shown encouraging results. There has been no evidence of exacerbation of inflammation in these studies. The quantity and quality of literature on the effects of PRP in treating joint pathologies in RA is limited. Preclinical studies show decrease in disease activity with good safety profile. Invitro studies show suppression of inflammation. Thus, the available literature is encouraging towards the use of PRP in RA. Larger trials and molecular studies to understand the exact role of platelets in disease pathogenesis and treatment mechanisms are needed to decide the future course of PRP in RA.

Available only for authorised users

McInnes IB, Schett G (2011) The pathogenesis of rheumatoid arthritis. N Engl J Med 365:2205–2219. https://doi.org/10.1056/NEJMra1004965CrossRefPubMed

Cooles FA, Isaacs JD (2011) Pathophysiology of rheumatoid arthritis. Curr Opin Rheumatol 23:233–240CrossRef

Nurmohamed MT, Dijkmans BA (2008) Are biologics more effective than classical disease-modifying antirheumatic drugs? Arthritis Res Ther 10:118. https://doi.org/10.1186/ar2491CrossRefPubMedPubMedCentral

Kumar LD, Karthik R, Gayathri N, Sivasudha T (2016) Advancement in contemporary diagnostic and therapeutic approaches for rheumatoid arthritis. Biomed Pharmacother Biomedecine Pharmacother 79:52–61. https://doi.org/10.1016/j.biopha.2016.02.001CrossRef

Ruderman EM (2012) Overview of safety of non-biologic and biologic DMARDs. Rheumatol Oxf Engl 51(Suppl 6):vi37-43. https://doi.org/10.1093/rheumatology/kes283CrossRef

Chen X, Jones IA, Park C, Vangsness CT (2018) The efficacy of platelet-rich plasma on tendon and ligament healing: a systematic review and meta-analysis with bias assessment. Am J Sports Med 46:2020–2032. https://doi.org/10.1177/0363546517743746CrossRefPubMed

Johal H, Khan M, Yung S-HP et al (2019) Impact of platelet-rich plasma use on pain in orthopaedic surgery: a systematic review and meta-analysis. Sports Health 11:355–366. https://doi.org/10.1177/1941738119834972CrossRefPubMedPubMedCentral

Hesseler MJ, Shyam N (2019) Platelet-rich plasma and its utility in medical dermatology: a systematic review. J Am Acad Dermatol 81:834–846. https://doi.org/10.1016/j.jaad.2019.04.037CrossRefPubMed

Dhillon RS, Schwarz EM, Maloney MD (2012) Platelet-rich plasma therapy—future or trend? Arthritis Res Ther 14:219. https://doi.org/10.1186/ar3914CrossRefPubMedPubMedCentral

10.

Cruciani M, Franchini M, Mengoli C et al (2019) Platelet-rich plasma for sports-related muscle, tendon and ligament injuries: an umbrella review. Blood Transfus Trasfus Sangue 17:465–478. https://doi.org/10.2450/2019.0274-19CrossRef

11.

Colli S, Maderna P, Tremoli E et al (1982) Platelet-function in rheumatoid-arthritis. Scand J Rheumatol 11:139–143CrossRef

12.

Endresen G (1989) Evidence for activation of platelets in the synovial-fluid from patients with rheumatoid-arthritis. Rheumatol Int 9:19–24CrossRef

13.

Pazdur J, Kopec M (1970) Platelets in rheumatoid arthritis. Thromb Diath Haemorrh 23:276PubMed

14.

Andia I (2017) The ins and outs of platelets in RA. Nat Rev Rheumatol 13:262–263CrossRef

15.

Olumuyiwa-Akeredolu O, Page MJ, Soma P, Pretorius E (2019) Platelets: emerging facilitators of cellular crosstalk in rheumatoid arthritis. Nat Rev Rheumatol 15:237–248CrossRef

16.

Cochrane Handbook for Systematic Reviews of Interventions. Cochrane-handbook-systematic-reviews-interventions. Accessed 6 Nov 2020

17.

Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. https://journals.plos.org/plosmedicine/article?id=https://doi.org/10.1371/journal.pmed.1000097. Accessed 6 Nov 2020

18.

Hooijmans CR, Rovers MM, de Vries RB et al (2014) SYRCLE’s risk of bias tool for animal studies. BMC Med Res Methodol 14:43. https://doi.org/10.1186/1471-2288-14-43CrossRefPubMedPubMedCentral

19.

Pan W, Dai C, Li Y et al (2020) PRP-chitosan thermoresponsive hydrogel combined with black phosphorus nanosheets as injectable biomaterial for biotherapy and phototherapy treatment of rheumatoid arthritis. Biomaterials 239:119851CrossRef

20.

Yan S, Yang B, Shang C et al (2016) Platelet-rich plasma promotes the migration and invasion of synovial fibroblasts in patients with rheumatoid arthritis. Mol Med Rep 14:2269–2275CrossRef

21.

Tong S, Liu J, Zhang C (2017) Platelet-rich plasma inhibits inflammatory factors and represses rheumatoid fibroblast-like synoviocytes in rheumatoid arthritis. Clin Exp Med 17:441–449CrossRef

22.

Wang W, Liu J, Yang B et al (2017) Modulation of platelet-derived microparticles to adhesion and motility of human rheumatoid arthritis fibroblast-like synoviocytes. PLoS One 12(7):e0181003CrossRef

23.

Tohidnezhad M, Bayer A, Rasuo B et al (2017) Platelet-released growth factors modulate the secretion of cytokines in synoviocytes under inflammatory joint disease. Mediators Inflamm 2017:1046438CrossRef

24.

Lippross S, Moeller B, Haas H et al (2011) Intraarticular injection of platelet-rich plasma reduces inflammation in a pig model of rheumatoid arthritis of the knee joint. ARTHRITIS Rheum 63:3344–3353CrossRef

25.

Shafik NM, El-Esawy RO, Mohamed DA et al (2019) Regenerative effects of glycyrrhizin and/or platelet rich plasma on type-II collagen-induced arthritis: targeting autophay machinery markers, inflammation and oxidative stress. Arch Biochem Biophys 675:108095. https://doi.org/10.1016/j.abb.2019.108095CrossRefPubMed

26.

Tong S, Zhang C, Liu J (2017) Platelet-rich plasma exhibits beneficial effects for rheumatoid arthritis mice by suppressing inflammatory factors. Mol Med Rep 16:4082–4088CrossRef

27.

Badsha H, Harifi G, Murrell WD (2020) Platelet-rich plasma for treatment of rheumatoid arthritis: case series and review of literature. Case Rep Rheumatol 2020:8761485PubMedPubMedCentral

28.

Habets KL, Huizinga TW, Toes RE (2013) Platelets and autoimmunity. Eur J Clin Invest 43:746–757CrossRef

29.

Cafaro G, Bartoloni E, Alunno A, Gerli R (2019) Platelets: a potential target for rheumatoid arthritis treatment? Expert Rev Clin Immunol 15:1–3CrossRef

30.

Gasparyan AY, Ayvazyan L, Pretorius E, Kitas GD (2014) Platelets in rheumatic diseases: friend or foe? Curr Pharm Des 20:552–566CrossRef

31.

Işık M, Şahin H, Hüseyin E (2014) New platelet indices as inflammatory parameters for patients with rheumatoid arthritis. Eur J Rheumatol 1:144–146. https://doi.org/10.5152/eurjrheumatol.2014.140023CrossRefPubMedPubMedCentral

32.

Boilard E, Nigrovic PA, Larabee K et al (2010) Platelets amplify inflammation in arthritis via collagen-dependent microparticle production. Science 327:580–583. https://doi.org/10.1126/science.1181928CrossRefPubMedPubMedCentral

33.

Rosengren S, Corr M, Boyle DL (2010) Platelet-derived growth factor and transforming growth factor beta synergistically potentiate inflammatory mediator synthesis by fibroblast-like synoviocytes. Arthritis Res Ther 12:R65. https://doi.org/10.1186/ar2981CrossRefPubMedPubMedCentral

34.

Ahamed J, Burg N, Yoshinaga K et al (2008) In vitro and in vivo evidence for shear-induced activation of latent transforming growth factor-β1. Blood 112:3650–3660. https://doi.org/10.1182/blood-2008-04-151753CrossRefPubMedPubMedCentral

35.

Brown AJ, Sepuru KM, Sawant KV, Rajarathnam K (2017) Platelet-derived chemokine CXCL7 dimer preferentially exists in the glycosaminoglycan-bound form: implications for neutrophil-platelet crosstalk. Front Immunol 8:1248. https://doi.org/10.3389/fimmu.2017.01248CrossRefPubMedPubMedCentral

36.

Wang M-J, Huang Y, Huang R-Y et al (2015) Determination of role of thromboxane A2 in rheumatoid arthritis. Discov Med 19:23–32PubMed

37.

Jenne CN, Urrutia R, Kubes P (2013) Platelets: bridging hemostasis, inflammation, and immunity. Int J Lab Hematol 35:254–261. https://doi.org/10.1111/ijlh.12084CrossRefPubMed

38.

Smith TL, Weyrich AS (2011) Platelets as central mediators of systemic inflammatory responses. Thromb Res 127:391–394. https://doi.org/10.1016/j.thromres.2010.10.013CrossRefPubMed

39.

von Hundelshausen P, Weber C (2007) Platelets as immune cells: bridging inflammation and cardiovascular disease. Circ Res 100:27–40. https://doi.org/10.1161/01.RES.0000252802.25497.b7CrossRef

40.

Aslam R, Speck ER, Kim M et al (2006) Platelet Toll-like receptor expression modulates lipopolysaccharide-induced thrombocytopenia and tumor necrosis factor-alpha production in vivo. Blood 107:637–641. https://doi.org/10.1182/blood-2005-06-2202CrossRefPubMed

41.

Elzey BD, Ratliff TL, Sowa JM, Crist SA (2011) Platelet CD40L at the interface of adaptive immunity. Thromb Res 127:180–183. https://doi.org/10.1016/j.thromres.2010.10.011CrossRefPubMed

42.

Andia I, Maffulli N (2013) Platelet-rich plasma for managing pain and inflammation in osteoarthritis. Nat Rev Rheumatol 9:721–730. https://doi.org/10.1038/nrrheum.2013.141CrossRefPubMed

43.

Stocker TJ, Hellen I-A, Steffen M, Christian S (2017) Small but mighty: platelets as central effectors of host defense. Thromb Haemost 117:651–661. https://doi.org/10.1160/TH16-12-0921CrossRefPubMed

44.

Nurden AT (2011) Platelets, inflammation and tissue regeneration. Thromb Haemost 105(Suppl 1):S13-33. https://doi.org/10.1160/THS10-11-0720CrossRefPubMed

45.

Anitua E, Sánchez M, Nurden AT et al (2007) Platelet-released growth factors enhance the secretion of hyaluronic acid and induce hepatocyte growth factor production by synovial fibroblasts from arthritic patients. Rheumatol Oxf Engl 46:1769–1772. https://doi.org/10.1093/rheumatology/kem234CrossRef

46.

Mishra A, Tummala P, King A et al (2009) Buffered platelet-rich plasma enhances mesenchymal stem cell proliferation and chondrogenic differentiation. Tissue Eng Part C Methods 15:431–435. https://doi.org/10.1089/ten.tec.2008.0534CrossRefPubMedPubMedCentral

47.

Krüger JP, Hondke S, Endres M et al (2012) Human platelet-rich plasma stimulates migration and chondrogenic differentiation of human subchondral progenitor cells. J Orthop Res Off Publ Orthop Res Soc 30:845–852. https://doi.org/10.1002/jor.22005CrossRef

48.

Zamora C, Cantó E, Nieto JC et al (2017) Binding of platelets to lymphocytes: a potential anti-inflammatory therapy in rheumatoid arthritis. J Immunol 198:3099–3108. https://doi.org/10.4049/jimmunol.1601708CrossRefPubMed

49.

van Buul GM, Koevoet WLM, Kops N et al (2011) Platelet-rich plasma releasate inhibits inflammatory processes in osteoarthritic chondrocytes. Am J Sports Med 39:2362–2370. https://doi.org/10.1177/0363546511419278CrossRefPubMed

50.

Sánchez M, Guadilla J, Fiz N, Andia I (2012) Ultrasound-guided platelet-rich plasma injections for the treatment of osteoarthritis of the hip. Rheumatol Oxf Engl 51:144–150. https://doi.org/10.1093/rheumatology/ker303CrossRef

51.

Patel S, Dhillon MS, Aggarwal S et al (2013) Treatment with platelet-rich plasma is more effective than placebo for knee osteoarthritis: a prospective, double-blind, randomized trial. Am J Sports Med 41:356–364. https://doi.org/10.1177/0363546512471299CrossRefPubMed

52.

Giuggioli D, Colaci M, Manfredi A et al (2012) Platelet gel in the treatment of severe scleroderma skin ulcers. Rheumatol Int 32:2929–2932. https://doi.org/10.1007/s00296-011-2038-0CrossRefPubMed

53.

Chakravdhanula U, Anbarasu K, Verma VK, Beevi SS (2016) Clinical efficacy of platelet-rich plasma in combination with methotrexate in chronic plaque psoriatic patients. Dermatol Ther 29:446–450. https://doi.org/10.1111/dth.12388CrossRefPubMed

54.

Everts PAM, Knape JTA, Weibrich G et al (2006) Platelet-rich plasma and platelet gel: a review. J Extra Corpor Technol 38:174–187PubMedPubMedCentral

55.

Anitua E, Orive G (2010) Short implants in maxillae and mandibles: a retrospective study with 1 to 8 years of follow-up. J Periodontol 81:819–826. https://doi.org/10.1902/jop.2010.090637CrossRefPubMed

56.

Spero JA (1993) Bovine thrombin-induced inhibitor of factor V and bleeding risk in postoperative neurosurgical patients. Report of three cases. J Neurosurg 78:817–820. https://doi.org/10.3171/jns.1993.78.5.0817CrossRefPubMed

57.

Bl C, Ja S, Gj M, Re C (1993) Redo cardiac surgery: late bleeding complications from topical thrombin-induced factor V deficiency. J Thorac Cardiovasc Surg 105:222–7 (discussion 227)CrossRef

58.

Sampson S, Gerhardt M, Mandelbaum B (2008) Platelet-rich plasma injection grafts for musculoskeletal injuries: a review. Curr Rev Musculoskelet Med 1:165–174. https://doi.org/10.1007/s12178-008-9032-5CrossRefPubMedPubMedCentral

Title: “Platelet-rich plasma holds promise in management of rheumatoid arthritis”—systematic review
Authors: Girinivasan Chellamuthu
Sathish Muthu
Manish Khanna
Venus Khanna
Publication date: 01-11-2021
Publisher: Springer Berlin Heidelberg
Keywords: Arthritis
Rheumatoid Arthritis
Published in: Rheumatology International / Issue 11/2021
Print ISSN: 0172-8172
Electronic ISSN: 1437-160X
DOI: https://doi.org/10.1007/s00296-021-04849-9

ACC 2024 Congress Coverage

Heart Failure Video

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

“Platelet-rich plasma holds promise in management of rheumatoid arthritis”—systematic review

Abstract

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 11/2021

Methotrexate and interstitial lung disease. Is there a real causative factor?

Clinical performance of rheumatoid arthritis impact of disease score: a real-life evidence from the multicenter nationwide registry BioStaR

Pulmonary nodular lymphoid hyperplasia and Sjögren’s syndrome: a case report and literature review

The impact of the COVID-19 pandemic on patients with primary Sjögren syndrome

Bibliometric analysis of publication activity in the field of familial Mediterranean fever in 2010–2019: a Scopus-based study

COVID-19 and fertility—at the crossroads of autoimmunity and thrombosis

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page